Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
D

Daiken Biomedical Co Ltd
TWSE:7780

Watchlist Manager
Daiken Biomedical Co Ltd
TWSE:7780
Watchlist
Price: 16.7 TWD -0.6%
Market Cap: NT$13.5B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Daiken Biomedical Co Ltd

There are no price targets for Daiken Biomedical Co Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Daiken Biomedical Co Ltd Competitors:
Price Targets

Revenue
Forecast

26% / Year
Past Growth
44% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
26% / Year
Past Growth
44% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 2 years is 44%.

What are analyst estimates?

Gross Profit
Forecast

22% / Year
Past Growth
47% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
22% / Year
Past Growth
47% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Gross Profit has been 22%. The projected CAGR for the next 2 years is 47%.

What are analyst estimates?

Operating Income
Forecast

19% / Year
Past Growth
92% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
19% / Year
Past Growth
92% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 2 years is 92%.

What are analyst estimates?

Pre-Tax Income
Forecast

46% / Year
Past Growth
60% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
46% / Year
Past Growth
60% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 46%. The projected CAGR for the next 2 years is 60%.

What are analyst estimates?

Net Income
Forecast

45% / Year
Past Growth
57% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
45% / Year
Past Growth
57% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Net Income has been 45%. The projected CAGR for the next 2 years is 57%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Daiken Biomedical Co Ltd's stock price target?
Not Available

Daiken Biomedical Co Ltd does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Daiken Biomedical Co Ltd?
Projected CAGR
44%

Over the last 2 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 2 years is 44%.

What is the Gross Profit forecast for Daiken Biomedical Co Ltd?
Projected CAGR
47%

Over the last 2 years, the compound annual growth rate for Gross Profit has been 22%. The projected CAGR for the next 2 years is 47%.

What is the Operating Income forecast for Daiken Biomedical Co Ltd?
Projected CAGR
92%

Over the last 2 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 2 years is 92%.

What is the Pre-Tax Income forecast for Daiken Biomedical Co Ltd?
Projected CAGR
60%

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 46%. The projected CAGR for the next 2 years is 60%.

What is the Net Income forecast for Daiken Biomedical Co Ltd?
Projected CAGR
57%

Over the last 2 years, the compound annual growth rate for Net Income has been 45%. The projected CAGR for the next 2 years is 57%.

Back to Top
ALPHA SPREAD
Follow us
Join 352,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett